143 related articles for article (PubMed ID: 37592432)
1. Deciphering molecular complexity of HCV-associated lymphoproliferation.
Merli M; Passamonti F; Arcaini L
Br J Haematol; 2023 Oct; 203(2):154-157. PubMed ID: 37592432
[TBL] [Abstract][Full Text] [Related]
2. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?
Visentini M; Fiorilli M; Casato M
Expert Rev Hematol; 2017 Aug; 10(8):719-727. PubMed ID: 28675071
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C cure with antiviral therapy--benefits beyond the liver.
Soriano V; Labarga P; Fernandez-Montero JV; de Mendoza C; Esposito I; Benítez-Gutiérrez L; Barreiro P
Antivir Ther; 2016; 21(1):1-8. PubMed ID: 26110692
[TBL] [Abstract][Full Text] [Related]
4. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
5. B-cell Clonality in HCV-Induced Patients Treated with Oral Direct-Acting Antiviral Agents.
Waly B; Abdel-Aal MT; El-Etreby S; Saleh LM; El Baz A; Abdel-Ghaffar H
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2187-2193. PubMed ID: 37378951
[TBL] [Abstract][Full Text] [Related]
6. Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders.
Mazzaro C; Visentini M; Gragnani L; Vit F; Tissino E; Pozzo F; Papotti R; Casato M; Zignego AL; Bittolo T; Zucchetto A; Degan M; Bomben R; Gattei V
Br J Haematol; 2023 Oct; 203(2):237-243. PubMed ID: 37491625
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study.
Di Stasio D; Lucchese A; Romano A; Adinolfi LE; Serpico R; Marrone A
Clin Oral Investig; 2022 Aug; 26(8):5409-5417. PubMed ID: 35477818
[TBL] [Abstract][Full Text] [Related]
8. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
Toyoda H; Kikuchi K
Ther Apher Dial; 2023 Oct; 27(5):831-838. PubMed ID: 37217295
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus (HCV) infection and lymphoproliferative disorders.
Libra M; Gasparotto D; Gloghini A; Navolanic PM; De Re V; Carbone A
Front Biosci; 2005 Sep; 10():2460-71. PubMed ID: 15970508
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents.
Schiavinato A; Zanetto A; Pantano G; Tosato F; Nabergoj M; Fogar P; Piva E; Gambato M; Franceschet E; Floreani A; Farinati F; Burra P; Russo FP; Plebani M
J Viral Hepat; 2017 Dec; 24(12):1168-1176. PubMed ID: 28643451
[TBL] [Abstract][Full Text] [Related]
12. Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit.
Zanotti P; Izzo I; Casari S; Cattaneo C; Zaltron S; Spinetti A; Odolini S; Chirico C; Grecchi C; Festa E; Castelli F
New Microbiol; 2017 Oct; 40(4):289-290. PubMed ID: 28825444
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
14. From hepatitis C virus infection to B-cell lymphoma.
Couronné L; Bachy E; Roulland S; Nadel B; Davi F; Armand M; Canioni D; Michot JM; Visco C; Arcaini L; Besson C; Hermine O
Ann Oncol; 2018 Jan; 29(1):92-100. PubMed ID: 29045541
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy.
Mazzaro C; Bomben R; Gragnani L; Visentini M; Pozzato G; Pozzo F; Zucchetto A; Gattei V
Semin Hematol; 2022 Oct; 59(4):177-182. PubMed ID: 36805885
[TBL] [Abstract][Full Text] [Related]
16. Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis.
Gragnani L; Lorini S; Martini L; Stasi C; Visentini M; Petraccia L; Marello N; Monti M; Marri S; Madia F; Ricca V; Zignego AL
Clin Rheumatol; 2022 Jan; 41(1):147-157. PubMed ID: 34409558
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic manifestations of HCV: the role of direct acting antivirals.
Polo ML; Laufer N
Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
19. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
20. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
Tajiri K; Okada K; Ito H; Kawai K; Kashii Y; Tokimitsu Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
BMC Gastroenterol; 2023 May; 23(1):182. PubMed ID: 37231349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
